Relmada Therapeutics, Inc.
RLMD
$4.80
$0.051.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.62M | 11.37M | 12.26M | 6.29M | 7.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.01M | 19.46M | 17.43M | 10.33M | 10.22M |
| Operating Income | -15.01M | -19.46M | -17.43M | -10.33M | -10.22M |
| Income Before Tax | -12.91M | -19.05M | -19.87M | -10.09M | -9.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.91M | -19.05M | -19.87M | -10.09M | -9.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.91M | -19.05M | -19.87M | -10.09M | -9.87M |
| EBIT | -15.01M | -19.46M | -17.43M | -10.33M | -10.22M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.11 | -0.22 | -0.33 | -0.30 | -0.30 |
| Normalized Basic EPS | -0.07 | -0.13 | -0.17 | -0.19 | -0.19 |
| EPS Diluted | -0.11 | -0.22 | -0.33 | -0.30 | -0.30 |
| Normalized Diluted EPS | -0.07 | -0.13 | -0.17 | -0.19 | -0.19 |
| Average Basic Shares Outstanding | 112.38M | 86.60M | 61.10M | 33.19M | 33.19M |
| Average Diluted Shares Outstanding | 112.38M | 86.60M | 61.10M | 33.19M | 33.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |